PubMed · 14804065
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1951. TRANSITIONAL cell papilloma.. https://pubmed.ncbi.nlm.nih.gov/14804065/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The transcription factor Forkhead-box A1 (Foxa1), a member of the FOX class of transcription factors, has been implicated in the pathogenesis of lung, esophageal and prostate cancers. We have recently identified transcriptional activation of p27 by FOXA1. In this study, we analyzed the activities and expression pattern of FOXA1 in breast cancer. Forced expression of FOXA1 inhibited clonal growth of breast cancer cell lines, and FOXA1 levels inversely correlated with growth stimuli. In the estrogen receptor (ER)-positive MCF-7 cells, FOXA1 increased p27 promoter activity and inhibited the ER pathway activity. Analysis of FOXA1 expression in breast tissue arrays revealed significantly higher expression in pure ductal carcinomas in situ compared to invasive ductal carcinomas (IDC); and in IDC, high expression of FOXA1 was associated with favorable prognostic factors. Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer.
A simultaneous bilateral back-projection method for 3D dynamic contrast-enhanced (DCE)-MRI of the breasts was developed and evaluated. Using a double-side band modulation of the RF slab excitation pulse, discontinuous volumes that included both breasts were simultaneously selected. The number of slice phase-encoding steps was undersampled by a factor of 2, and the resulting signal aliasing from one volume to the other was removed using SENSE processing. In-plane encoding was performed with an interleaved radial acquisition reconstructed using dynamic k-space-weighted image contrast (KWIC) temporal filtering. Image resolution was 0.5 x 0.5 x 3.0 mm(3) with an effective temporal resolution of 15 s for both breast volumes. Combined with the 2x acceleration from SENSE encoding, this is a 16x acceleration factor over a conventional MR bilateral breast scan. An initial evaluation of these methods was performed on a cohort of women who presented with palpable or mammographically visible breast abnormalities. A total of 73 abnormalities were found in 45 of the 54 bilateral examinations that were performed. In 11 of these cases there was a significant finding in the contralateral breast. DCE images of both breasts can be acquired simultaneously, resulting in high-resolution images as well as rapid sampling of the contrast kinetics.
PURPOSE: The aim of this study was to evaluate whether quantitative changes in contrast enhancement (CE) after neoadjuvant chemotherapy (NC) are associated with histological signs of tumor regression and whether quantitative dynamic MRI (dMRI) is capable of accurately assessing preoperative tumor size compared to mammography (MG) and ultrasound (US). METHODS: Thirty-one patients with breast cancer underwent MRI before and after NC. Dynamic CE was measured using a turbo-FLASH sequence and quantified by a two-compartment model, where two parameters, k(ep) (distribution constant rate) and A (amplitude), were calculated and color mapped. RESULTS: When tumors had signs of histological regression in the operative specimen (n=17) decrease of the parameters A and k(ep) was significantly more marked compared to tumors without regression (n=12). The correlation between tumor size measured by dMRI and histopathology was 0.81 when areas of unspecific CE were included; when they were not included the correlation was 0.66 and tumor size was systematically underestimated. In 26 patients dMRI was retrospectively compared with MG (r=0.51; dMRI, r=0.80) and in 22 patients with US (r=0.60; dMRI, r=0.75). CONCLUSION: Changes in dynamic CE are associated with histological tumor regression. Quantitative dMRI enables a valid assessment of tumor residue and is superior to MG and US. Remaining unspecific CE within the original tumor site should be considered as potentially malignant.